Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies

Using Spectral Flow Cytometry for CAR T-Cell Clinical Trials: Game Changing Technologies Enabling Novel Therapies

The monitoring of chimeric antigen redirected (CAR) T-cells post-infusion in clinical trials is crucial for determining the success of the therapy. Data generated during clinical trials will be used to monitor therapeutic response, assess the success of the therapy, and identify predictive biomarkers. It is essential to have a robust, standardized assay for reliable data collection, requiring validation, calibration, technology transfer, standardization, and regulatory compliance.